Future Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer

Dr. Pedro Barata and Dr. Johann De Bono discuss the future direction of radiopharmaceutical therapies and emerging treatment strategies in metastatic castration-resistant prostate cancer (mCRPC). Dr. De Bono reviews how radiopharmaceuticals are expected to play an increasingly important role as patients progress through currently available therapies, including androgen receptor pathway inhibitors and chemotherapy. The discussion explores the evolving positioning of PSMA-targeted therapies, including potential future roles for alpha-emitting actinium-based agents alongside existing beta-emitting radioligand therapies. Dr. De Bono also highlights ongoing investigations evaluating radiopharmaceuticals in combination with PARP inhibitors and other novel systemic approaches. In addition, the faculty discuss broader therapeutic developments in mCRPC, including antibody-drug conjugates, T-cell engagers, and other emerging targeted therapies that may further reshape treatment sequencing in the coming years. The segment concludes with discussion of encouraging early-phase data from the PANTHA study and the importance of long-term safety monitoring, multidisciplinary coordination, and continued clinical research as the radiopharmaceutical landscape continues to evolve.